证券代码：688373 证券简称：盟科药业 公告编号：2025-040 上海盟科药业股份有限公司 第二届董事会第十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海盟科药业股份有限公司（以下简称"公司"）第二届董事会第十九次 会议的通知于2025年9月17日发出，于2025年9月22日在公司会议室通过现场表 决与通讯表决相结合的方式召开（以下简称"本次会议"）。本次会议应出席 董事7人，实际出席董事7人。本次会议由董事长ZHENGYU YUAN（袁征宇） 先生主持。本次会议的召开符合《中华人民共和国公司法》（以下简称"《公 司法》"）及其他有关法律法规和《上海盟科药业股份有限公司章程》（以下 简称"《公司章程》"）的规定，合法、有效。 经与会董事充分审议和表决，会议形成决议如下： 一、审议通过《关于公司符合向特定对象发行股票条件的议案》 根据《公司法》《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司证券发行注册管理办法》（以下简称"《管理办法》"）等相关法 律法规及规范性文件，公司对上市公 ...

（文章来源：每日经济新闻） 每经AI快讯，9月22日，盟科药业(688373.SH)公告称，海鲸药业与公司签署《附生效条件的向特定对象 发行股份认购协议》，拟认购公司1.64亿股，发行完成后将持有20.00%股份，成为公司控股股东，自然 人张现涛将成为公司实际控制人；本次权益变动属于增持，不触及要约收购。 ...

此次发行前，公司无控股股东、实控人。发行完成后，海鲸药业将持有公司20%股份。同时，此次发行 后，公司董事会设置9名董事，其中3名独立董事，海鲸药业将向公司董事会提名5名董事，超过董事半 数。海鲸药业成为公司控股股东，自然人张现涛将成为公司实控人。 人民财讯9月22日电，盟科药业(688373)9月22日公告，公司拟向南京海鲸药业股份有限公司(简称"海鲸 药业")发行股票募资不超过10.33亿元(含)，扣除发行费用后全部用于公司日常研发与经营投入。 ...

上海盟科药业股份有限公司（以下简称"公司"）于 2025 年 9 月 22 日召开 第二届董事会第十九次会议和第二届监事会第十四次会议，审议通过了《关于公 司向特定对象发行股票预案的议案》等相关议案。根据相关要求，现就本次向特 定对象发行股票公司不存在直接或通过利益相关方向参与认购的投资者提供财 务资助或补偿事宜承诺如下： 公司不存在向发行对象作出保底保收益或变相保底保收益承诺的情形，亦不 存在直接或通过利益相关方向参与认购的投资者提供任何财务资助或者补偿的 情形。 特此公告。 上海盟科药业股份有限公司董事会 2025 年 9 月 23 日 证券代码：688373 证券简称：盟科药业 公告编号：2025-044 上海盟科药业股份有限公司 关于本次向特定对象发行股票不存在直接或通过利益相关方向 发行对象提供财务资助或补偿的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ...

盟科药业公告，公司为进一步增强公司综合竞争力，根据公司发展需要，拟向特定对象发行A股股票募 集资金总额不超过103,257.86万元，扣除发行费用后，实际募集资金将全部用于公司日常研发与经营投 入。本次发行完成后，公司控股股东将变更为海鲸药业，自然人张现涛将成为公司实际控制人。 ...

Group 1 - JinkoSolar's subsidiary plans to sell 80% stake in Jinko New Materials for 80 million yuan, which will no longer be included in JinkoSolar's consolidated financial statements [1] - Zhongtai Automobile's subsidiary has been forced to dismantle its T300 vehicle assembly line, making it unable to resume production this year, leading to uncertainty in its ongoing operational capacity [1] - Springlight Technology's shareholders plan to reduce their holdings by a total of 0.68% of the company's shares between October 9, 2025, and January 8, 2026 [2] Group 2 - Sentech's energy storage and charging integration business is in the expansion phase, with its main business focusing on building-integrated photovoltaics (BIPV) and environmental remediation [3] - Qinchuan IoT plans to reduce its holdings by up to 1% of the company's shares from October 9, 2025, to January 8, 2026, with proceeds to be used for working capital [4] - Redick's shareholder plans to reduce holdings by up to 2% of the company's shares starting from September 9, 2025 [5] Group 3 - Guangxun Technology plans to raise up to 3.5 billion yuan through a private placement to fund various projects, including optical connection and high-speed optical transmission product production [8] - Shanghai Electric has terminated its acquisition of K-Electric Limited, which was planned for 1.773 billion USD, and is now focusing on investing in offshore photovoltaic and wind power projects [9][10] - Longsoft Technology's shareholder intends to transfer 1.72% of the company's shares through a non-public transfer [10] Group 4 - Amgen Pharmaceuticals' shareholders plan to reduce their holdings by a total of 6% of the company's shares between October 9, 2025, and January 8, 2026 [11] - Juhe Materials intends to acquire the blank mask business from SKE for approximately 35 million yuan to expand its semiconductor materials business [12] - Linuo Medical Packaging's shareholder plans to reduce holdings by up to 3% of the company's shares from October 9, 2025, to January 8, 2026 [13] Group 5 - Dongzhu Ecology plans to acquire 89.49% of Kairuixing Technology through a combination of share issuance and cash payment, aiming to enter the satellite communication and space information technology sector [14] - Dabeinong's controlling shareholder plans to reduce holdings by up to 1.99% of the company's shares starting from September 10, 2025 [15] - Tianji Technology is promoting the industrialization of lithium sulfide material preparation patents, currently in the early stages of development [16] Group 6 - Jing Shan Light Machine's subsidiary has secured a procurement order worth approximately 1.005 billion yuan from a leading lithium battery company [17] - Daheng Technology plans to establish a wholly-owned subsidiary with an investment of 600 million yuan to expand its semiconductor business [18]

Core Viewpoint - Mengke Pharmaceutical's stock price has declined significantly, currently trading at 7.27 yuan, representing a drop of 7.03%, and is in a state of loss since its IPO [1] Group 1: Company Overview - Mengke Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 5, 2022, with an initial public offering (IPO) of 13 million shares at a price of 8.16 yuan per share [1] - The stock reached a peak price of 14.20 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Financial Performance - The total amount raised from the IPO was 1.0608 billion yuan, with a net amount of 959.7279 million yuan after deducting issuance costs [1] - The net amount raised was 290.1495 million yuan less than the original plan of 1.2498774 billion yuan, which was intended for innovative drug research and development, marketing channel upgrades, academic promotion projects, and working capital [1] - The total issuance costs amounted to 101.0721 million yuan, with underwriting and sponsorship fees accounting for 79.0296 million yuan [1]

（文章来源：每日经济新闻） 每经AI快讯，9月10日，盟科药业跌逾6%。消息面上，公司昨日公告称多名股东拟合计减持不超6%公 司股份。 ...

Group 1 - The core point of the article is that Mengke Pharmaceutical (688373.SH) has seen a decline of 6.27%, currently trading at 7.33 yuan, with a market capitalization of 4.8 billion yuan [1] - Major shareholders BestIdea, JSR, and GPTMT plan to reduce their holdings by up to 39.3363 million shares, which represents no more than 6% of the company's total share capital [1] - The reduction in shareholding is primarily driven by the shareholders' own funding needs [1]

Group 1 - The core point of the news is that Shanghai Mengke Pharmaceutical Co., Ltd. announced a share reduction plan by its major shareholders, which may impact the stock price and investor sentiment [1] - Best Idea International Limited holds approximately 58.44 million shares, accounting for 8.91% of the total shares of the company [1] - JSR Limited and GP TMT Holdings Limited hold approximately 30.84 million shares (4.7%) and 18.37 million shares (2.8%) respectively, with JSR and GP TMT being acting in concert, collectively holding about 49.22 million shares (7.51%) [1] Group 2 - The shareholders plan to reduce their holdings by up to approximately 39.34 million shares, which is not more than 6% of the total share capital of the company [1] - As of the announcement, the market capitalization of Mengke Pharmaceutical is 5.1 billion yuan [2]